Openbookopenbook
Equity
ACAD
+0.0 · +0.00%
USD · NASDAQ

ACADIA Pharmaceuticals Inc(ACAD) Stock Analysis | Healthcare

USD --+0.00%
Reward64Moderate
Risk29Low
75%Data
Strong 33% profit margin · Revenue growing 16% YoY
Growth Machine
Market Cap:5.08Bn
ⓘ
Reward Rating
64
Moderate
Reward Assessment
75% data coverage
Top 50% of stocksView factors
ⓘ
Risk Rating
29
Low
Risk Assessment

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ACAD to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ACAD, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $33.85.

What is ACADIA Pharmaceuticals Inc?

, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ACAD · Verdict

Solid reward · low risk

ACAD stands out on balance sheet and growth, but watch the valuation signal.

Based on 88% data coverage

ACAD · Verdict

What’s working & what to watch

Strengths 4

  • Balance sheet100/100

    Current ratio 3.83

  • Growth89/100

    Revenue +27.5% CAGR

  • Cash flow80/100

    10% free-cash-flow margin

  • Profitability74/100

    36% net margin · 36% ROE

Watchouts 1

  • Valuation11/100

    P/E 71.9× · PEG 50.86

Model-based scoring. For information only — not financial advice.

What is ACADIA Pharmaceuticals Inc?

, a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 5.08B, and a P/E ratio of 13.2x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: Moderate (64)

The scoring profile indicates moderate reward potential, with growth and profitability as the leading contributors. Risk indicators are low, suggesting a relatively contained downside profile.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

APLSMid Cap / 5.3B market cap
Apellis Pharmaceuticals Inc
Compare
DYNMid Cap / 4.9B market cap
Dyne Therapeutics Inc
Compare
EWTXMid Cap / 4.8B market cap
Edgewise Therapeutics Inc
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap5.08B
P/E Ratio13.2287
Dividend YieldN/A
Beta0.845
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
23,739 shares
$83k
0
6-9months
16,950 shares
$162k
0
9-12months
549,444 shares
$1.1M
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.